CNX Therapeutics has appointed David Flint as Chief Corporate Development Officer (CCDO).
Flint is an experienced M&A and corporate development executive with a strong track record of originating and executing complex transactions across the industry, most recently at UCB and Solvay. He brings broad international experience spanning EMEA, the Americas and Asia.
In his new role, Flint will lead the company’s corporate development function, driving the identification and execution of strategic partnerships, licensing agreements and acquisitions that accelerate the company’s pan-European expansion.
Flint joins CNX at a pivotal moment in the company’s European growth journey, bringing a distinguished track record in corporate M&A and strategic development across the pharmaceutical and life sciences sectors.
Guy Clark, CEO of CNX Therapeutics, said: “David’s exceptional experience leading complex, high-value transactions in the pharmaceutical sector, combined with his deep understanding of European markets, makes him ideally placed to help us realise our ambitious growth strategy.”
David Flint, CCDO at CNX Therapeutics, said: “The company has built an impressive portfolio and strong reputation, and I see tremendous opportunity to build on that foundation through thoughtful, value-creating partnerships and transactions.”
CNX Therapeutics is a specialty pharmaceutical company focused on improving patient access to essential medicines.